Clinical study of intelligent tongue diagnosis and oral microbiome for classifying TCM syndromes in MASLD
- PMID: 40442807
- PMCID: PMC12121174
- DOI: 10.1186/s13020-025-01118-w
Clinical study of intelligent tongue diagnosis and oral microbiome for classifying TCM syndromes in MASLD
Abstract
Background: This study aimed to analyze the tongue image features and oral microbial markers in different TCM syndromes related to metabolic dysfunction-associated steatotic liver disease (MASLD).
Methods: This study involved 34 healthy volunteers and 66 MASLD patients [36 with Dampness-Heat (DH) and 30 with Qi-Deficiency (QD) syndrome]. Oral microbiome analysis was conducted through 16S rRNA sequencing. Tongue image feature extraction used the Uncertainty Augmented Context Attention Network (UACANet), while syndrome classification was performed using five different machine learning methods based on tongue features and oral microbiota.
Results: Significant differences in tongue color, coating, and oral microbiota were noted between DH band QD syndromes in MASLD patients. DH patients exhibited a red-crimson tongue color with a greasy coating and enriched Streptococcus and Rothia on the tongue. In contrast, QD patients displayed a pale tongue with higher abundances of Neisseria, Fusobacterium, Porphyromonas and Haemophilus. Combining tongue image characteristics with oral microbiota differentiated DH and QD syndromes with an AUC of 0.939 and an accuracy of 85%.
Conclusion: This study suggests that tongue characteristics are related to microbial metabolism, and different MASLD syndromes possess distinct biomarkers, supporting syndrome classification.
Keywords: Machine learning; Metabolic dysfunction-associated steatotic liver disease (MASLD); Microbial metabolism; TCM syndromes; Tongue diagnosis.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: This study has been approved by the ethics committee of Shuguang Hospital Affiliated to Shanghai University of TCM. The ethics committee number is 2020-916-125-01, and the clinical trial registration number is ChiCTR2100043546. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.
Figures







References
-
- Alisi A, McCaughan G, Grønbæk H. Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact. Hepatol Int. 2024. 10.1007/s12072-024-10674-6. - PubMed
-
- Quetglas-Llabrés MM, Monserrat-Mesquida M, Bouzas C, García S, Mateos D, Casares M, et al. Effects of a two year lifestyle intervention on intrahepatic fat reduction and renal health: mitigation of inflammation and oxidative stress, a randomized trial. Antioxid Basel Switz. 2024;13:754. 10.3390/antiox13070754. - PMC - PubMed
-
- Zong X, Zhang H, Yang T. Analysis of traditional Chinese medicine syndrome types and frequency changes of CD8+ and CD25+ T cells in metabolic-related fatty liver disease. Cell Mol Biol Noisy Gd Fr. 2023;69:126–31. 10.14715/cmb/2023.69.15.22. - PubMed
Grants and funding
- 82104738/Innovative Research Group Project of the National Natural Science Foundation of China
- 2023M732337/China Postdoctoral Science Foundation
- ZYYZDXK-2023069/State Administration of Traditional Chinese Medicine of the People's Republic of China
- 20244Y0129/Shanghai Municipal Health Commission
- 2022509/Intelligence Community Postdoctoral Research Fellowship Program
LinkOut - more resources
Full Text Sources